Abstract
In this work we report the identification of unknown degradation products observed during the accelerated stability studies of a Hepatitis C Virus inhibitor drug product by using LC/MS and forced degradation studies. These degradation products are formed through chemical interaction between the Active Pharmaceutical Ingredient (API) and meglumine, an excipient in the drug formulation.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
